Bringing Vision to Life, Together

Our team integrates vision with next-generation science and technology
to enable new options for tough-to-treat cancers.

Vivacitas Oncology is a private clinical stage biopharmaceutical company focused on tough-to-treat cancers resistant to current treatment modalities.

Next-generation technology

Vivacitas’ lead candidate ( AR-67) is a novel lipophilic compound targeting improved efficacy and tolerability.

Proprietary synthesis

Vivacitas maintains intellectual property defining systems and methods for camptothecin analog synthesis.

Patient-focused innovation

The team shares a common belief that our primary focus and responsibilities are to patients with cancer and their families.

Forging a new way forward

Vivacitas is supported by a highly respected team of medical advisors and researchers as we assess, develop, and transform select therapies to unlock their treatment potential.

Our Science

Vivacitas lead compound, AR-67, is a synthetic, highly lipophilic derivative of the natural alkaloid camptothecin, with potential antineoplastic and radiosensitizing activities (Bom et al, 2000; Chen et al, 2005). AR-67 has improved physicochemical properties compared to other camptothecin-derived therapies.

Clinical data from Phase I and II trials in multiple tumor types demonstrate AR-67’s treatment potential. Phase II data in recurrent glioblastoma (brain cancer) showed potential of progression free survival of 6-29 months and less severe side effects (e.g. Grade 4 diarrhea).

AR-67 received Orphan Drug Designation from the FDA for Glioblastoma.

Our Expertise

Our scientists, clinicians, industry executives, and medical advisors came together with a shared mission: to improve the lives of cancer patients by gaining power over the disease.

Each is an accomplished professional and their combined expertise is a force de rigueur in combating the hardest to treat cancers.

Vivacitas applies integrity, clarity, tenacity, collaboration, and teamwork to pursue superior results in the lives of cancer patients.

Investors

Vivacitas is seeking investors and partners to enable continued development and potential registration of AR-67 in multiple solid tumors. Successful Phase II study results will potentially lead to a strategic exit.

Additional details on investment opportunities are available upon request.

Lorem ipsum dolor sit amet Vivamus id

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Eget rhoncus viverra tristique aliq uam et praesent adipiscing turpis auris.

Recent news

Walnut Creek, CA, USA, January 18, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, will be attending and presenting a poster on its lead asset, AR-67 at the 3rd Annual Glioblastoma Drug Development Summit, a virtual event held from January 18th to 20th, 2022.

Read More

Walnut Creek, CA, USA, January 17, 2022 – Vivacitas Oncology, Inc., a privately-held oncology company focused on tough–to–treat cancers, proudly announces that Dr. Erkut Borazanci, MD, has joined its Pancreatic Medical Advisory Board.

Read More

WALNUT CREEK, CALIFORNIA, US, January 10, 2022 – Vivacitas Oncology, Inc. (“Vivacitas” or the “Company”), a privately held clinical stage biopharmaceutical company focused on tough–to–treat cancers, today announced it will present at the 2022 Biotech Showase™ conference with an on-line presentation.

Read More

References

1. Novel silatecan displays high lipophilicity, improved blood stability and potent
anticancer activity. Bom D, et al J Med Chem 2000; 43:3970-3980

2. Silatecan DB-67 is a novel DNA Topo-1 targeted radiation sensitizer: Chen AY. Mol
Cancer Ther 2005; 4(2): 317-24.

3. Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680

4. Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40,
published in Neuro-Oncology(https://academic.oup.com/neuro-oncology)

5. Ubiquitin-dependent Destruction of Topoisomerase I Is
Stimulated by the Antitumor Drug Camptothecin*, Desai et al. The Journal of Biological Chemistry, Vol. 272, No. 39, Issue of September 26, pp. 24159–24164, 1997.  https://www.jbc.org

6. Metabolic Pathways of the Camptothecin Analog AR-67, Horn et al. Drug Metabolism and Disposition, Vol. 39, No. 4, 37390/3672838, 2011. https://dmd.aspetjournals.org